 Brian Freed
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 7 | 2016 | 97 | 1.750 |
Why?
| | T-Lymphocytes | 21 | 2018 | 1774 | 1.630 |
Why?
| | Epitopes | 4 | 2016 | 443 | 1.370 |
Why?
| | Genetic Predisposition to Disease | 6 | 2016 | 2275 | 0.980 |
Why?
| | HLA Antigens | 8 | 2019 | 230 | 0.970 |
Why?
| | Lymphocyte Activation | 19 | 2006 | 1067 | 0.960 |
Why?
| | Interleukin-2 | 16 | 2005 | 416 | 0.870 |
Why?
| | Arthritis, Rheumatoid | 3 | 2016 | 989 | 0.850 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 72 | 0.820 |
Why?
| | Hydroquinones | 6 | 2003 | 25 | 0.790 |
Why?
| | Kidney Transplantation | 20 | 2019 | 585 | 0.780 |
Why?
| | HLA-DR Antigens | 5 | 2020 | 224 | 0.670 |
Why?
| | Tars | 3 | 2006 | 4 | 0.630 |
Why?
| | Graft Rejection | 14 | 2019 | 555 | 0.620 |
Why?
| | Alleles | 7 | 2019 | 832 | 0.600 |
Why?
| | Immunosuppressive Agents | 13 | 2017 | 681 | 0.580 |
Why?
| | Acrolein | 2 | 2007 | 24 | 0.570 |
Why?
| | Vimentin | 2 | 2016 | 62 | 0.550 |
Why?
| | Cyclosporins | 11 | 1991 | 60 | 0.540 |
Why?
| | HLA-B Antigens | 2 | 2022 | 55 | 0.490 |
Why?
| | Catechols | 4 | 2003 | 16 | 0.490 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 260 | 0.480 |
Why?
| | Peptides | 2 | 2016 | 879 | 0.470 |
Why?
| | Tissue Donors | 6 | 2018 | 336 | 0.470 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2022 | 177 | 0.470 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2022 | 355 | 0.430 |
Why?
| | Fetal Blood | 6 | 2024 | 272 | 0.430 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 197 | 0.430 |
Why?
| | Cord Blood Stem Cell Transplantation | 5 | 2016 | 96 | 0.410 |
Why?
| | Smoking | 5 | 2011 | 1487 | 0.410 |
Why?
| | B-Lymphocytes | 7 | 2021 | 770 | 0.410 |
Why?
| | DNA | 7 | 2007 | 1388 | 0.400 |
Why?
| | Smoke | 5 | 2007 | 143 | 0.400 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 827 | 0.380 |
Why?
| | Humans | 90 | 2024 | 118974 | 0.360 |
Why?
| | Ribonucleotide Reductases | 2 | 2000 | 30 | 0.350 |
Why?
| | Graft Survival | 9 | 2017 | 504 | 0.350 |
Why?
| | Immunoglobulin G | 4 | 2013 | 788 | 0.340 |
Why?
| | Immunoglobulin E | 1 | 2010 | 365 | 0.330 |
Why?
| | Arachis | 1 | 2010 | 152 | 0.330 |
Why?
| | Lymphocytes | 3 | 2013 | 347 | 0.310 |
Why?
| | Disease Models, Animal | 5 | 2021 | 3730 | 0.310 |
Why?
| | Cells, Cultured | 11 | 2019 | 4077 | 0.300 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 26 | 0.300 |
Why?
| | Isoantibodies | 3 | 2017 | 63 | 0.290 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 204 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 984 | 0.280 |
Why?
| | Plants, Toxic | 3 | 2000 | 28 | 0.280 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2006 | 32 | 0.280 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 37 | 0.280 |
Why?
| | Flow Cytometry | 5 | 2016 | 1085 | 0.270 |
Why?
| | Tuberculosis | 2 | 2023 | 240 | 0.270 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 266 | 0.270 |
Why?
| | Immune System | 2 | 2021 | 181 | 0.270 |
Why?
| | Histocompatibility Testing | 7 | 2019 | 123 | 0.270 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 540 | 0.260 |
Why?
| | Ethylmaleimide | 3 | 1991 | 18 | 0.260 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 827 | 0.250 |
Why?
| | Antibodies | 3 | 2019 | 392 | 0.250 |
Why?
| | Haplotypes | 3 | 2014 | 473 | 0.250 |
Why?
| | Ganciclovir | 4 | 1997 | 46 | 0.250 |
Why?
| | Cell Line | 10 | 2016 | 2707 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2014 | 3360 | 0.230 |
Why?
| | Cytomegalovirus Infections | 5 | 1997 | 187 | 0.230 |
Why?
| | Gene Frequency | 3 | 2019 | 513 | 0.230 |
Why?
| | Islets of Langerhans | 3 | 1994 | 739 | 0.220 |
Why?
| | Transplantation, Haploidentical | 1 | 2022 | 7 | 0.220 |
Why?
| | HLA-A Antigens | 1 | 2022 | 50 | 0.220 |
Why?
| | HLA-C Antigens | 1 | 2022 | 32 | 0.210 |
Why?
| | Cyclosporine | 5 | 1998 | 173 | 0.210 |
Why?
| | Cigarette Smoking | 1 | 2023 | 85 | 0.210 |
Why?
| | Protein Binding | 3 | 2016 | 1975 | 0.210 |
Why?
| | Interferon-gamma | 3 | 2005 | 736 | 0.210 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 102 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1171 | 0.210 |
Why?
| | Enoxaparin | 1 | 2022 | 51 | 0.200 |
Why?
| | Receptors, KIR | 2 | 2022 | 89 | 0.200 |
Why?
| | Central Tolerance | 1 | 2021 | 8 | 0.200 |
Why?
| | In Vitro Techniques | 9 | 2005 | 1094 | 0.200 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1346 | 0.200 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 33 | 0.200 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 81 | 0.190 |
Why?
| | Immune Tolerance | 3 | 2021 | 334 | 0.190 |
Why?
| | HLA-DRB4 Chains | 1 | 2020 | 6 | 0.190 |
Why?
| | Transplantation, Homologous | 9 | 2019 | 415 | 0.190 |
Why?
| | Heterografts | 1 | 2021 | 130 | 0.190 |
Why?
| | Receptors, Interleukin-2 | 5 | 2003 | 65 | 0.190 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2445 | 0.180 |
Why?
| | Brain Ischemia | 1 | 2024 | 310 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 156 | 0.180 |
Why?
| | Nickel | 1 | 2020 | 53 | 0.180 |
Why?
| | Trace Elements | 1 | 2020 | 46 | 0.180 |
Why?
| | Immunotherapy | 2 | 2021 | 493 | 0.180 |
Why?
| | Cell Division | 4 | 1997 | 776 | 0.180 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2021 | 101 | 0.180 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 454 | 0.180 |
Why?
| | Mice | 17 | 2023 | 15520 | 0.180 |
Why?
| | Transcription Factors | 2 | 2005 | 1570 | 0.180 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 115 | 0.170 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 48 | 0.170 |
Why?
| | Insulin | 3 | 1994 | 2162 | 0.170 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 565 | 0.170 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 16 | 0.170 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 47 | 0.170 |
Why?
| | Vascular System Injuries | 1 | 2019 | 70 | 0.170 |
Why?
| | Tacrolimus | 2 | 2017 | 151 | 0.170 |
Why?
| | Unrelated Donors | 2 | 2024 | 38 | 0.170 |
Why?
| | Transcription, Genetic | 2 | 2003 | 1323 | 0.160 |
Why?
| | HEK293 Cells | 2 | 2022 | 625 | 0.160 |
Why?
| | Animals | 25 | 2023 | 33381 | 0.160 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 19 | 0.160 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 126 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 73 | 0.150 |
Why?
| | Antiviral Agents | 3 | 2020 | 654 | 0.150 |
Why?
| | Hydrogen Peroxide | 3 | 1988 | 305 | 0.150 |
Why?
| | Cell Transplantation | 1 | 1997 | 39 | 0.150 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 94 | 0.150 |
Why?
| | Donor Selection | 1 | 2018 | 73 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 200 | 0.150 |
Why?
| | Proinsulin | 1 | 1997 | 48 | 0.150 |
Why?
| | Carcinogenesis | 1 | 2018 | 182 | 0.150 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 363 | 0.150 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 156 | 0.150 |
Why?
| | Benzoquinones | 1 | 1997 | 44 | 0.150 |
Why?
| | Complement System Proteins | 1 | 2019 | 294 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 900 | 0.150 |
Why?
| | Hypersensitivity | 1 | 2020 | 268 | 0.140 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1206 | 0.140 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 2071 | 0.140 |
Why?
| | Female | 28 | 2021 | 61565 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 164 | 0.140 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 34 | 0.140 |
Why?
| | Genetic Variation | 2 | 2015 | 926 | 0.140 |
Why?
| | Dextrans | 1 | 2016 | 74 | 0.140 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.140 |
Why?
| | Collagen Type II | 1 | 2016 | 48 | 0.140 |
Why?
| | Autoantibodies | 4 | 2021 | 1335 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 204 | 0.140 |
Why?
| | Interleukin-1 | 1 | 2000 | 980 | 0.140 |
Why?
| | Adult | 18 | 2019 | 31512 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 398 | 0.130 |
Why?
| | Genetic Therapy | 1 | 1997 | 267 | 0.130 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 372 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 667 | 0.130 |
Why?
| | Genotype | 3 | 2022 | 1882 | 0.130 |
Why?
| | Resting Phase, Cell Cycle | 2 | 2006 | 15 | 0.130 |
Why?
| | Stroke | 1 | 2024 | 1047 | 0.130 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 516 | 0.130 |
Why?
| | Methylprednisolone | 3 | 1991 | 84 | 0.130 |
Why?
| | G1 Phase | 2 | 2006 | 68 | 0.130 |
Why?
| | Clonal Anergy | 1 | 1994 | 54 | 0.130 |
Why?
| | Protein Kinase C | 1 | 1996 | 297 | 0.120 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 233 | 0.120 |
Why?
| | Retrospective Studies | 9 | 2022 | 12978 | 0.120 |
Why?
| | Endothelial Cells | 1 | 2019 | 732 | 0.120 |
Why?
| | Autoimmunity | 2 | 2021 | 831 | 0.120 |
Why?
| | Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.120 |
Why?
| | Lymphocyte Culture Test, Mixed | 7 | 1996 | 46 | 0.120 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 874 | 0.120 |
Why?
| | Indoles | 1 | 1996 | 316 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 409 | 0.120 |
Why?
| | Cell Cycle | 3 | 2006 | 550 | 0.120 |
Why?
| | C-Reactive Protein | 2 | 1987 | 360 | 0.120 |
Why?
| | Dried Blood Spot Testing | 1 | 2013 | 68 | 0.120 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 303 | 0.120 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 26 | 0.110 |
Why?
| | Male | 22 | 2021 | 57801 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 740 | 0.110 |
Why?
| | Models, Biological | 1 | 2020 | 1715 | 0.110 |
Why?
| | Radioimmunoassay | 5 | 1990 | 165 | 0.110 |
Why?
| | Models, Animal | 2 | 2013 | 363 | 0.110 |
Why?
| | Transduction, Genetic | 1 | 2013 | 116 | 0.110 |
Why?
| | Postoperative Complications | 5 | 2017 | 2235 | 0.110 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 45 | 0.110 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 68 | 0.110 |
Why?
| | Leukemia L1210 | 1 | 1992 | 7 | 0.110 |
Why?
| | Child, Preschool | 6 | 2014 | 9491 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 310 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 628 | 0.110 |
Why?
| | Lung | 4 | 2007 | 3664 | 0.100 |
Why?
| | Middle Aged | 12 | 2019 | 27617 | 0.100 |
Why?
| | Chagas Disease | 1 | 2012 | 34 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 311 | 0.100 |
Why?
| | Beryllium | 2 | 2005 | 151 | 0.100 |
Why?
| | Fibroblasts | 2 | 1994 | 842 | 0.100 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 34 | 0.100 |
Why?
| | Bronchiolitis Obliterans | 1 | 2012 | 66 | 0.100 |
Why?
| | Mice, Knockout | 5 | 2021 | 2680 | 0.100 |
Why?
| | Blood Banks | 1 | 2011 | 43 | 0.100 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 15 | 0.100 |
Why?
| | Chromatography, High Pressure Liquid | 7 | 2005 | 490 | 0.100 |
Why?
| | Transplantation Chimera | 1 | 2011 | 51 | 0.100 |
Why?
| | Maleimides | 1 | 1991 | 23 | 0.100 |
Why?
| | Calcium | 2 | 1994 | 1169 | 0.100 |
Why?
| | International Cooperation | 1 | 2011 | 177 | 0.100 |
Why?
| | Serine Endopeptidases | 2 | 2022 | 105 | 0.100 |
Why?
| | Receptors, Transferrin | 2 | 2003 | 23 | 0.100 |
Why?
| | Spleen | 1 | 2013 | 510 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1390 | 0.100 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2016 | 451 | 0.090 |
Why?
| | Mitogens | 2 | 1988 | 57 | 0.090 |
Why?
| | Algorithms | 1 | 2018 | 1541 | 0.090 |
Why?
| | Skin Tests | 1 | 2010 | 135 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2013 | 455 | 0.090 |
Why?
| | Cesarean Section | 1 | 2011 | 165 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 359 | 0.090 |
Why?
| | Antibody Formation | 1 | 1991 | 276 | 0.090 |
Why?
| | Survival Rate | 5 | 2017 | 1720 | 0.090 |
Why?
| | Nicotine | 2 | 2023 | 276 | 0.090 |
Why?
| | Jurkat Cells | 2 | 2000 | 134 | 0.090 |
Why?
| | Siblings | 1 | 2010 | 235 | 0.090 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 19 | 0.090 |
Why?
| | Lung Transplantation | 1 | 2012 | 263 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1323 | 0.090 |
Why?
| | Cricetinae | 3 | 1994 | 262 | 0.090 |
Why?
| | Adolescent | 7 | 2014 | 18480 | 0.090 |
Why?
| | Base Sequence | 3 | 2012 | 2159 | 0.080 |
Why?
| | HLA-DQ Antigens | 2 | 2000 | 176 | 0.080 |
Why?
| | Disease Susceptibility | 1 | 2011 | 331 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1995 | 128 | 0.080 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 112 | 0.080 |
Why?
| | Cell Survival | 3 | 1997 | 1047 | 0.080 |
Why?
| | Anemia, Sickle Cell | 1 | 2012 | 230 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 702 | 0.080 |
Why?
| | Phytohemagglutinins | 4 | 1991 | 27 | 0.080 |
Why?
| | Allografts | 2 | 2019 | 135 | 0.080 |
Why?
| | Amino Acids | 1 | 2011 | 465 | 0.080 |
Why?
| | Cell Differentiation | 4 | 2021 | 1753 | 0.080 |
Why?
| | Mice, Nude | 2 | 2020 | 663 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 574 | 0.080 |
Why?
| | Genetic Linkage | 2 | 2006 | 321 | 0.080 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2871 | 0.080 |
Why?
| | Isoantigens | 1 | 1987 | 19 | 0.070 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 81 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2179 | 0.070 |
Why?
| | Follow-Up Studies | 5 | 2018 | 4596 | 0.070 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 82 | 0.070 |
Why?
| | Prognosis | 4 | 2017 | 3443 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 1998 | 546 | 0.070 |
Why?
| | Kidney Function Tests | 2 | 2017 | 164 | 0.070 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 12 | 0.070 |
Why?
| | Aldehydes | 1 | 2007 | 154 | 0.070 |
Why?
| | Muromonab-CD3 | 2 | 1997 | 23 | 0.070 |
Why?
| | Enzyme Induction | 1 | 2006 | 94 | 0.070 |
Why?
| | Lung Diseases | 2 | 2006 | 718 | 0.070 |
Why?
| | Sequence Homology | 1 | 2006 | 40 | 0.070 |
Why?
| | Butylated Hydroxytoluene | 1 | 2006 | 32 | 0.070 |
Why?
| | Bone Marrow | 2 | 2021 | 255 | 0.070 |
Why?
| | Cysteine | 1 | 2007 | 184 | 0.070 |
Why?
| | Phenotype | 3 | 2021 | 3003 | 0.070 |
Why?
| | Arginine | 1 | 2007 | 249 | 0.070 |
Why?
| | Microspheres | 1 | 2006 | 130 | 0.070 |
Why?
| | HLA-DP Antigens | 1 | 2005 | 33 | 0.070 |
Why?
| | Child | 5 | 2014 | 19129 | 0.070 |
Why?
| | Autoantigens | 2 | 2021 | 397 | 0.070 |
Why?
| | Cell Proliferation | 2 | 2020 | 2275 | 0.070 |
Why?
| | Phospholipases A | 1 | 2006 | 101 | 0.070 |
Why?
| | Phenols | 1 | 2006 | 85 | 0.070 |
Why?
| | Transfection | 2 | 1998 | 888 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2005 | 135 | 0.070 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 33 | 0.060 |
Why?
| | Aged | 5 | 2018 | 19657 | 0.060 |
Why?
| | Arteriosclerosis | 1 | 2005 | 88 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2004 | 64 | 0.060 |
Why?
| | Reoperation | 3 | 1998 | 557 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2005 | 194 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 4708 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2005 | 148 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 224 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2011 | 3171 | 0.060 |
Why?
| | Structure-Activity Relationship | 3 | 1991 | 522 | 0.060 |
Why?
| | Pandemics | 2 | 2024 | 1355 | 0.060 |
Why?
| | Agglutination | 2 | 1997 | 5 | 0.060 |
Why?
| | Berylliosis | 1 | 2005 | 183 | 0.060 |
Why?
| | Risk Factors | 6 | 2017 | 9000 | 0.060 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 34 | 0.060 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 83 | 0.060 |
Why?
| | Concanavalin A | 3 | 1988 | 74 | 0.060 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 55 | 0.060 |
Why?
| | Lectins, C-Type | 1 | 2003 | 63 | 0.060 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 683 | 0.060 |
Why?
| | Immunophenotyping | 2 | 2015 | 278 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2021 | 2025 | 0.060 |
Why?
| | Biomarkers | 2 | 2019 | 3588 | 0.060 |
Why?
| | Mesocricetus | 2 | 1992 | 31 | 0.060 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 331 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 369 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2005 | 308 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 339 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 136 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 642 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2674 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2003 | 115 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 576 | 0.050 |
Why?
| | Cell Communication | 2 | 2013 | 281 | 0.050 |
Why?
| | Drug Synergism | 2 | 1996 | 339 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2022 | 222 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1987 | 158 | 0.050 |
Why?
| | Neutrophils | 2 | 2005 | 1233 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 2 | 2016 | 396 | 0.050 |
Why?
| | Leukemia | 2 | 2012 | 208 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Iron Chelating Agents | 1 | 2000 | 17 | 0.050 |
Why?
| | Kidney | 4 | 2019 | 1353 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 65 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 76 | 0.050 |
Why?
| | RNA | 2 | 1997 | 833 | 0.050 |
Why?
| | Antioxidants | 2 | 2006 | 564 | 0.050 |
Why?
| | Cell Separation | 2 | 2011 | 296 | 0.050 |
Why?
| | Virus Internalization | 1 | 2020 | 41 | 0.050 |
Why?
| | Antibody Specificity | 1 | 2001 | 184 | 0.050 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 10 | 0.050 |
Why?
| | Apoptosis | 2 | 2020 | 2484 | 0.050 |
Why?
| | Biopsy | 2 | 2019 | 1079 | 0.050 |
Why?
| | Antigens, CD | 1 | 2003 | 460 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 359 | 0.050 |
Why?
| | Antithrombins | 1 | 2020 | 51 | 0.050 |
Why?
| | Free Radicals | 1 | 2000 | 104 | 0.050 |
Why?
| | Extracellular Traps | 1 | 2020 | 40 | 0.050 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 80 | 0.050 |
Why?
| | Dimerization | 1 | 2000 | 183 | 0.050 |
Why?
| | Inflammation | 3 | 2006 | 2566 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 567 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 333 | 0.050 |
Why?
| | Nephelometry and Turbidimetry | 2 | 2013 | 16 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 273 | 0.050 |
Why?
| | Blotting, Western | 2 | 2004 | 1194 | 0.050 |
Why?
| | Gene Expression | 1 | 2005 | 1489 | 0.050 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 47 | 0.050 |
Why?
| | Tyrosine | 1 | 2000 | 233 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 9342 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 12 | 0.040 |
Why?
| | Luminescent Measurements | 2 | 2013 | 72 | 0.040 |
Why?
| | Young Adult | 2 | 2016 | 10793 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1687 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 1999 | 33 | 0.040 |
Why?
| | Xenobiotics | 1 | 1999 | 25 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 1900 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 1999 | 49 | 0.040 |
Why?
| | Steroid 21-Hydroxylase | 1 | 1999 | 29 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 1991 | 1284 | 0.040 |
Why?
| | Addison Disease | 1 | 1999 | 39 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 24 | 0.040 |
Why?
| | Metallothionein | 1 | 1998 | 24 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 143 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2013 | 98 | 0.040 |
Why?
| | Immunoglobulin M | 2 | 1991 | 253 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 80 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 84 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 509 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 1998 | 79 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 75 | 0.040 |
Why?
| | Pokeweed Mitogens | 2 | 1988 | 6 | 0.040 |
Why?
| | Depression, Chemical | 1 | 1997 | 23 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2005 | 2657 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 965 | 0.040 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 35 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1997 | 141 | 0.040 |
Why?
| | Acute Lung Injury | 1 | 2020 | 310 | 0.040 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 49 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 465 | 0.040 |
Why?
| | Complement Activation | 1 | 2019 | 350 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 5255 | 0.040 |
Why?
| | New York | 1 | 1997 | 118 | 0.040 |
Why?
| | Sulfhydryl Compounds | 2 | 1991 | 179 | 0.040 |
Why?
| | Guanidines | 1 | 1996 | 37 | 0.040 |
Why?
| | Contraindications | 1 | 2016 | 86 | 0.040 |
Why?
| | S Phase | 1 | 1996 | 74 | 0.040 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 47 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 175 | 0.040 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 6 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 202 | 0.030 |
Why?
| | Half-Life | 2 | 1996 | 147 | 0.030 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2015 | 18 | 0.030 |
Why?
| | Liver | 3 | 2007 | 1816 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 273 | 0.030 |
Why?
| | Iron | 1 | 1997 | 248 | 0.030 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 66 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2015 | 96 | 0.030 |
Why?
| | Cross Reactions | 3 | 1990 | 116 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 5 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 155 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 2016 | 113 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 281 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2016 | 148 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2326 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 299 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2001 | 1178 | 0.030 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 26 | 0.030 |
Why?
| | Mice, Inbred DBA | 2 | 1992 | 174 | 0.030 |
Why?
| | Thioguanine | 1 | 2013 | 20 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1994 | 443 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 418 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1993 | 81 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2013 | 136 | 0.030 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 4908 | 0.030 |
Why?
| | Umbilical Cord | 1 | 2013 | 84 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 119 | 0.030 |
Why?
| | Drug Resistance | 1 | 2013 | 167 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2013 | 204 | 0.030 |
Why?
| | Anticoagulants | 1 | 2016 | 559 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2013 | 128 | 0.030 |
Why?
| | Survival Analysis | 2 | 2012 | 1267 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 2851 | 0.030 |
Why?
| | Mercaptopurine | 1 | 1991 | 15 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 146 | 0.030 |
Why?
| | Lymphoma | 1 | 2012 | 180 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2062 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 4709 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 613 | 0.020 |
Why?
| | Blood Donors | 1 | 2011 | 109 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 191 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 332 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 690 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 953 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1597 | 0.020 |
Why?
| | Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| | Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 16 | 0.020 |
Why?
| | Colchicine | 1 | 1989 | 27 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1795 | 0.020 |
Why?
| | Monocytes | 2 | 1989 | 513 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 806 | 0.020 |
Why?
| | Blood Glucose | 1 | 1997 | 1939 | 0.020 |
Why?
| | DNA Replication | 1 | 1989 | 211 | 0.020 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 20 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1991 | 688 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 28 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 1987 | 8 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1868 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 182 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2006 | 49 | 0.020 |
Why?
| | Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 2006 | 77 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 2874 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2006 | 126 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 2995 | 0.020 |
Why?
| | Infant | 3 | 2007 | 8293 | 0.020 |
Why?
| | Cytosol | 1 | 2006 | 221 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 268 | 0.020 |
Why?
| | NADPH Dehydrogenase | 1 | 2005 | 8 | 0.020 |
Why?
| | NADH Dehydrogenase | 1 | 2005 | 18 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 1987 | 270 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 69 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 940 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 1987 | 272 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 2005 | 92 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2005 | 138 | 0.020 |
Why?
| | Blood Transfusion | 1 | 1987 | 306 | 0.020 |
Why?
| | Mice, Inbred AKR | 1 | 1983 | 34 | 0.020 |
Why?
| | Leukemia, Lymphoid | 1 | 1983 | 27 | 0.020 |
Why?
| | Leukemia, Experimental | 1 | 1983 | 27 | 0.010 |
Why?
| | Lymphokines | 1 | 1983 | 122 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 940 | 0.010 |
Why?
| | Necrosis | 1 | 1984 | 230 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1624 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 828 | 0.010 |
Why?
| | Rats | 3 | 2004 | 5392 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1384 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5116 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1991 | 1510 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 305 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2000 | 17 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 133 | 0.010 |
Why?
| | United States | 1 | 2016 | 12555 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 6471 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 5691 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 356 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2478 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 248 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 749 | 0.010 |
Why?
| | Azathioprine | 1 | 1998 | 51 | 0.010 |
Why?
| | Incidence | 2 | 1995 | 2424 | 0.010 |
Why?
| | Prednisone | 1 | 1998 | 235 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1996 | 46 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3057 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1996 | 113 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 1996 | 210 | 0.010 |
Why?
| | Risk | 1 | 1999 | 853 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1996 | 191 | 0.010 |
Why?
| | Dogs | 1 | 1996 | 371 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 1995 | 15 | 0.010 |
Why?
| | ABO Blood-Group System | 1 | 1995 | 35 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 1995 | 144 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1998 | 289 | 0.010 |
Why?
| | Species Specificity | 2 | 1988 | 565 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 327 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 94 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 380 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1995 | 542 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 1965 | 0.010 |
Why?
| | Length of Stay | 1 | 1994 | 1032 | 0.010 |
Why?
| | Rats, Inbred SHR | 1 | 1988 | 42 | 0.010 |
Why?
| | Deferoxamine | 1 | 1988 | 17 | 0.010 |
Why?
| | Malondialdehyde | 1 | 1988 | 30 | 0.010 |
Why?
| | Biotransformation | 1 | 1988 | 52 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 138 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1988 | 334 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1986 | 31 | 0.000 |
Why?
| | Kidney Medulla | 1 | 1986 | 32 | 0.000 |
Why?
| | Administration, Oral | 1 | 1988 | 756 | 0.000 |
Why?
| | Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| | Blood Physiological Phenomena | 1 | 1983 | 15 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1983 | 59 | 0.000 |
Why?
| | Thymidine | 1 | 1983 | 62 | 0.000 |
Why?
| | Kidney Diseases | 1 | 1988 | 439 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1983 | 394 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|